» Authors » Trine Zeeberg Iversen

Trine Zeeberg Iversen

Explore the profile of Trine Zeeberg Iversen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 674
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kjeldsen M, Jorgensen M, Gronseth D, Schonemann-Lund M, Nyvang G, Aaquist Haslund C, et al.
Cancer Res Commun . 2024 Nov; 4(12):3190-3200. PMID: 39591206
The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing...
2.
Kjeldsen J, Iversen T, Engell-Noerregaard L, Mellemgaard A, Andersen M, Marie Svane I
Front Immunol . 2018 Oct; 9:2145. PMID: 30283461
Long-term follow-up on a clinical trial of 15 stage III-IV NSCLC patients treated with an Indoleamine 2,3-Dioxygenase (IDO) peptide vaccine (NCT01219348). Fifteen HLA-A2-positive patients with stable stage III-IV NSCLC after...
3.
Anderson A, Todberg T, Kofoed K, Iversen T, Andersen M, Hjorth S, et al.
Ugeskr Laeger . 2018 Jan; 180(1). PMID: 29298742
A 59-year-old woman developed a rash and severe arthralgia, which primarily affected her fingers. She displayed digital arthritis and nodules on the hands, chest, face, and oral cavity. Blood samples...
4.
Nitschke N, Bjoern J, Iversen T, Andersen M, Marie Svane I
Stem Cell Investig . 2017 Oct; 4:77. PMID: 29057249
Background: Indoleamine 2,3-dioxygenase (IDO) and survivin have been identified as potential targets for cancer vaccination. In this phase II study a vaccine using the peptides Sur1M2 and IDO5 was combined...
5.
Kongsted P, Holz Borch T, Ellebaek E, Iversen T, Andersen R, Met O, et al.
Cytotherapy . 2017 Feb; 19(4):500-513. PMID: 28215654
Background Aims: We investigated whether the addition of an autologous dendritic cell-based cancer vaccine (DCvac) induces an immune response in patients with metastatic castration-resistant prostate cancer treated with docetaxel. Methods:...
6.
Holz Borch T, Engell-Noerregaard L, Iversen T, Ellebaek E, Met O, Hansen M, et al.
Oncoimmunology . 2016 Oct; 5(9):e1207842. PMID: 27757300
Introduction: Vaccination with dendritic cells (DCs) has generally not fulfilled its promise in cancer immunotherapy due to ineffective translation of immune responses into clinical responses. A proposed reason for this...
7.
Bjoern J, Iversen T, Nitschke N, Andersen M, Marie Svane I
Cytotherapy . 2016 Jul; 18(8):1043-1055. PMID: 27378345
Background Aim: Indoleamine 2,3-dioxygenase (IDO) is an emerging new target in cancer therapy that can be targeted with active immunotherapy (e.g. through peptide vaccination). Furthermore, IDO has been identified as...
8.
Bjoern J, Nitschke N, Iversen T, Schmidt H, Fode K, Marie Svane I
Oncoimmunology . 2016 May; 5(4):e1100788. PMID: 27141381
: Ipilimumab is effective in the treatment of metastatic malignant melanoma, but few biomarkers reliably predict treatment response. : Patients were treated with Ipilimumab for metastatic malignant melanoma. Blood and...
9.
Andersen R, Donia M, Ellebaek E, Holz Borch T, Kongsted P, Iversen T, et al.
Clin Cancer Res . 2016 Mar; 22(15):3734-45. PMID: 27006492
Purpose: Adoptive cell transfer therapy (ACT) based on autologous tumor-infiltrating lymphocytes (TIL) has achieved impressive clinical results in several phase I and II trials performed outside of Europe. Although transient,...
10.
Ruhlmann C, Iversen T, Okera M, Muhic A, Kristensen G, Feyer P, et al.
Radiother Oncol . 2015 Sep; 117(2):333-7. PMID: 26372344
Purpose: We aimed to prospectively assess the incidence, severity and patients' perceptions of side-effects induced by radiotherapy and concomitant weekly cisplatin. Patients And Methods: This multinational survey included patients with...